Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Boehringer Ingelheim
Dow
Express Scripts
Merck

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

ALLI Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Alli patents expire, and when can generic versions of Alli launch?

Alli is a drug marketed by Glaxosmithkline Cons and is included in one NDA.

The generic ingredient in ALLI is orlistat. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the orlistat profile page.

Drug patent expirations by year for ALLI
Drug Prices for ALLI

See drug prices for ALLI

Synonyms for ALLI
(-)-tetrahydrolipostatin
(-)-Tetrahydrolipstatin
(-)-Tetrahydrolipstatin; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl] dodecyl ester; Ro-18-0647
(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate
(2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester
(S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate
(S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl formyl-L-leucinate
[(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate
[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
111397-16-1
2-formamido-3-[(3-hexyl-4-oxo-oxetan-2-yl)methyl]-2-isobutyl-tetradecanoate
829O582
95M8R751W8
96829-58-2
AB00639987_10
AB00639987-09
AB1009256
AC1MHWQP
AHLBNYSZXLDEJQ-FWEHEUNISA-N
AKOS015894875
AN-15658
AOB6737
BC214880
BCP0726000044
BCP9001031
BDBM24567
BIDD:GT0853
C29H53NO5
CCG-100851
CHEBI:94686
CHEMBL175247
CPD000466339
CS-2165
D04028
DB01083
DTXSID8023395
FT-0082584
FT-0601570
GTPL5277
HMS2051I08
HSDB 7556
HY-B0218
J90006
KS-1183
L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-
L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
LEU002
LS-178328
MFCD05662360
MLS000759448
MLS001423955
MLS002207022
MolPort-005-938-035
N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester
N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
N-formyl-L-leucine-(S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]-dodecyl ester
N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone
NC00101
NCGC00165856-01
NCGC00165856-02
O0381
Orlipastat
Orlipastatum
Orlipastatum [INN-Latin]
orlistat
Orlistat (Alli, Xenical)
Orlistat (JAN/USAN/INN)
Orlistat [USAN:INN:BAN]
Orlistat [USAN:INN]
Orlistat, >=98%, solid
Orlistat, Pharmaceutical Secondary Standard; Certified Reference Material
Orlistat, United States Pharmacopeia (USP) Reference Standard
Orlistat,Tetrahydolipstat
orlistatum
PubChem18271
Q-201519
R-212
RL06088
Ro 18-0647/002
Ro 18-0647/008
Ro-18-0647
Ro-18-0647/002
Ro-180647-002
Ro-180647002
s1629
SAM001246637
SC-16265
SCHEMBL16408
SMR000466339
SR-01000759417
SR-01000759417-5
SR-01000759417-7
ST24048848
SW197481-2
tetrahydrolipastatin
Tetrahydrolipstatin
Tetrahydrolipstatin|||Ro 18-0647/002
THL
THLP
UNII-95M8R751W8
Xenical
Xenical (TN)
Z2379810072
ZINC8214635
ZLA0015
zlchem 13
Paragraph IV (Patent) Challenges for ALLI
Tradename Dosage Ingredient NDA Submissiondate
ALLI CAPSULE;ORAL orlistat 021887 2010-09-08

US Patents and Regulatory Information for ALLI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons ALLI orlistat CAPSULE;ORAL 021887-001 Feb 7, 2007 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Medtronic
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.